Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 14/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | HPGD | P15428 | 4/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | IKBKB | O14920 | 1/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.73 |
| ▸ | MAOA | P21397 | 1/20 | 0.73 |
| ▸ | MAOB | P27338 | 1/20 | 0.73 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804531 | 0.89 | TERT (0.81) | TERTBRD4KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6613794 | 0.88 | TERT (0.79) | TERTBRD4KDM4EALDH1A1CYP3A4 | |
| SCHEMBL31322174 | 0.88 | TERT (1.00) | TERTBRD4KDM4EALDH1A1CYP3A4 | |
| SCHEMBL4649959 | 0.88 | TERT (1.00) | TERTBRD4KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6618692 | 0.87 | TERT (0.76) | TERTBRD4KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6613071 | 0.85 | TERT (1.00) | TERTBRD4KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6802693 | 0.85 | TERT (0.74) | TERTBRD4KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6613454 | 0.85 | TERT (1.00) | TERTBRD4ALDH1A1CYP3A4MAPT | |
| SCHEMBL6614126 | 0.85 | TERT (1.00) | TERTBRD4KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6618127 | 0.85 | TERT (0.78) | TERTBRD4KDM4EALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281560-A1 | METHOD FOR PREVENTING AND/OR TREATING CANCER OR AUTOIMMUNE DISEASE WITH 3,4,2 Prime,3 Prime,4 Prime-PENTAHYDROXY-TRANS-CHALCONE | NATIONAL CHUNG HSING UNIVERSITY (TW) | 2025-09-11 | — | — | US | claimed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | claimed |
| US-20160367497-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY | 2016-12-22 | — | — | US | claimed |
| EP-2670404-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | The Trustees of Princeton University (US) | 2013-12-11 | — | — | EP | claimed |
| US-20130189383-A1 | USE OF ACACIA EXTRACTS AND THEIR COMPOUNDS ON INHIBITION OF XANTHINE OXIDASE | NATIONAL TAIWAN UNIVERSITY (TW) | 2013-07-25 | — | — | US | claimed |
| US-8414936-B2 | Use of Acacia extracts and their compounds on inhibition of xanthine oxidase | NATIONAL TAIWAN UNIVERSITY (TW) | 2013-04-09 | — | — | US | claimed |
| WO-2012106509-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-08-09 | — | — | WO | claimed |
| US-20120009288-A1 | USE OF ACACIA EXTRACTS AND THEIR COMPOUNDS ON INHIBITION OF XANTHINE OXIDASE | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-01-12 | — | — | US | claimed |
| US-20100310688-A1 | ACACIA EXTRACTS AND THEIR COMPOUNDS ON INHIBITION OF XANTHINE OXIDASE | NATIONAL TAIWAN UNIVERSITY (TW) | 2010-12-09 | — | — | US | claimed |
| US-20100047177-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY (US) | 2010-02-25 | — | — | US | claimed |
| US-20040242503-A1 | Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease | ATTENTION LABS INCORPORATED | 2004-12-02 | — | — | US | claimed |
| EP-1267853-B1 | COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE | PORTELA & CA SA (PT) | 2004-09-08 | — | — | EP | claimed |
| EP-1435930-A2 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2004-07-14 | — | — | EP | claimed |
| WO-2003032969-A2 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2003-04-24 | — | — | WO | claimed |
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1267853-A2 | COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE | Portela & Ca., S.A. (PT) | 2003-01-02 | — | — | EP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001068065-A9 | COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE | PORTELA & CA SA (PT) | 2002-07-18 | — | — | WO | claimed |
| WO-2001068065-A2 | COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE | PORTELA & COMPANHIA S.A. (PT) | 2001-09-20 | — | — | WO | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009288-A1 | USE OF ACACIA EXTRACTS AND THEIR COMPOUNDS ON INHIBITION OF XANTHINE OXIDASE | XDH, AOX1, ACACA | TERT 2205/4885BRD4 4101/4885KDM4E 1981/4885 |
| US-20040242503-A1 | Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease | COMT, DDC, AADAT | TERT 1828/4885BRD4 2867/4885KDM4E 976/4885 |
| US-20100310688-A1 | ACACIA EXTRACTS AND THEIR COMPOUNDS ON INHIBITION OF XANTHINE OXIDASE | XDH, ACACA, ACAT1 | TERT 2114/4885BRD4 3856/4885KDM4E 1895/4885 |
| US-20130189383-A1 | USE OF ACACIA EXTRACTS AND THEIR COMPOUNDS ON INHIBITION OF XANTHINE OXIDASE | XDH, AOX1, ACACA | TERT 2205/4885BRD4 4101/4885KDM4E 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.